AVEO Pharmaceuticals, Inc. (AVEO)
| Market Cap | 143.08M |
| Revenue (ttm) | 61.30M |
| Net Income (ttm) | -41.42M |
| Shares Out | 34.48M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,504 |
| Open | 4.15 |
| Previous Close | 4.25 |
| Day's Range | 4.03 - 4.24 |
| 52-Week Range | 3.06 - 7.59 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 15.71 (+278.6%) |
| Earnings Date | May 5, 2022 |
About AVEO
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addi...
Financial Performance
In 2021, AVEO's revenue was $42.30 million, an increase of 602.69% compared to the previous year's $6.02 million. Losses were -$53.34 million, 49.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for AVEO stock is "Buy." The 12-month stock price forecast is 15.71, which is an increase of 278.55% from the latest price.
News
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will par...
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AVEO Oncology Reports First Quarter 2022 Financial Results
– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million of FOTIVDA ® (tivozanib) U.S. Net Product Revenue –
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial ...
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
– Total 2021 Net Revenue of $42.3 Million –
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial resu...
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Act...
NEW YORK and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies and AVEO On...
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- ...
Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)
AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will pa...
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Co...
WILMINGTON, Del. & BOSTON--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with...
AVEO Oncology Highlights Recent Progress and 2022 Outlook
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Eval...
Manufacturing of Ficlatuzumab Clinical Supply to Commence in 2Q 2022; Initiation of Registrational Study in HPV Negative R/M HNSCC Expected in 1H 2023 Manufacturing of Ficlatuzumab Clinical Supply to Co...
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will pa...
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this r...
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two ...
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 6.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and...
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday,...
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or ...
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast T...
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -2.13% and -2.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: AVEO Pharmaceuticals Q2 Earnings
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.76% year over year to ($0.40), wh...
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021, and pr...